Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration

Kamilla Miskowiak; Becky Inkster; Sudhakar Selvaraj; Richard Wise; Guy M Goodwin; Catherine J Harmer

doi:10.1038/sj.npp.1301439

Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration

Kamilla Miskowiak, Becky Inkster, Sudhakar Selvaraj, Richard Wise, Guy M Goodwin, Catherine J Harmer

56 Citations (Scopus)

Abstract

Erythropoietin (Epo) has neuroprotective and neurotrophic effects and is a promising candidate for treatment of neurodegenerative and psychiatric disorder. Recently, we demonstrated that Epo modulates memory-relevant hippocampal response and fear processing in human models of antidepressant drug action 1 week post-administration, and improves self-reported mood for 3 days immediately following administration. The present study explored the effects of Epo (40 000 IU) vs saline on self-reported mood and on neural and cognitive function in healthy volunteers 3 days post-administration to test the reliability of the rapid mood improvement and its neuropsychological basis. Neuronal responses during the processing of happy and fearful faces were investigated using functional magnetic resonance imaging (fMRI); facial expression recognition performance was assessed after the fMRI scan. Daily ratings of mood were obtained for 3 days after Epo/saline administration. During faces processing Epo enhanced activation in the left amygdala and right precuneus to happy and fearful expressions. This was paired with improved recognition of all facial expressions, in particular of low intensity happiness and fear. This is similar to behavioral effects observed with acute administration of serotonergic antidepressants. Consistent with our previous finding, Epo improved self-reported mood for all 3 days post-administration. Together, these results suggest that characterization of the effects of Epo in a clinically depressed group is warranted.

Original language	English
Journal	Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Volume	33
Issue number	3
Pages (from-to)	611-8
Number of pages	8
ISSN	0893-133X
DOIs	https://doi.org/10.1038/sj.npp.1301439
Publication status	Published - Feb 2008

Keywords

Adult
Affect
Cognition
Double-Blind Method
Emotions
Erythrocyte Count
Erythropoietin
Facial Expression
Female
Hematocrit
Hemoglobins
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Oxygen
Photic Stimulation
Recognition (Psychology)
Recombinant Proteins
Social Perception
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.npp.1301439

Cite this

Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. / Miskowiak, Kamilla; Inkster, Becky; Selvaraj, Sudhakar et al.

In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Vol. 33, No. 3, 02.2008, p. 611-8.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{256af22c74144ceebaaa020fe91ecc89,

title = "Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration",

abstract = "Erythropoietin (Epo) has neuroprotective and neurotrophic effects and is a promising candidate for treatment of neurodegenerative and psychiatric disorder. Recently, we demonstrated that Epo modulates memory-relevant hippocampal response and fear processing in human models of antidepressant drug action 1 week post-administration, and improves self-reported mood for 3 days immediately following administration. The present study explored the effects of Epo (40 000 IU) vs saline on self-reported mood and on neural and cognitive function in healthy volunteers 3 days post-administration to test the reliability of the rapid mood improvement and its neuropsychological basis. Neuronal responses during the processing of happy and fearful faces were investigated using functional magnetic resonance imaging (fMRI); facial expression recognition performance was assessed after the fMRI scan. Daily ratings of mood were obtained for 3 days after Epo/saline administration. During faces processing Epo enhanced activation in the left amygdala and right precuneus to happy and fearful expressions. This was paired with improved recognition of all facial expressions, in particular of low intensity happiness and fear. This is similar to behavioral effects observed with acute administration of serotonergic antidepressants. Consistent with our previous finding, Epo improved self-reported mood for all 3 days post-administration. Together, these results suggest that characterization of the effects of Epo in a clinically depressed group is warranted.",

keywords = "Adult, Affect, Cognition, Double-Blind Method, Emotions, Erythrocyte Count, Erythropoietin, Facial Expression, Female, Hematocrit, Hemoglobins, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Male, Oxygen, Photic Stimulation, Recognition (Psychology), Recombinant Proteins, Social Perception, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "Kamilla Miskowiak and Becky Inkster and Sudhakar Selvaraj and Richard Wise and Goodwin, {Guy M} and Harmer, {Catherine J}",

year = "2008",

month = feb,

doi = "10.1038/sj.npp.1301439",

language = "English",

volume = "33",

pages = "611--8",

journal = "Neuropsychopharmacology",

issn = "0893-133X",

publisher = "nature publishing group",

number = "3",

}

TY - JOUR

T1 - Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration

AU - Miskowiak, Kamilla

AU - Inkster, Becky

AU - Selvaraj, Sudhakar

AU - Wise, Richard

AU - Goodwin, Guy M

AU - Harmer, Catherine J

PY - 2008/2

Y1 - 2008/2

N2 - Erythropoietin (Epo) has neuroprotective and neurotrophic effects and is a promising candidate for treatment of neurodegenerative and psychiatric disorder. Recently, we demonstrated that Epo modulates memory-relevant hippocampal response and fear processing in human models of antidepressant drug action 1 week post-administration, and improves self-reported mood for 3 days immediately following administration. The present study explored the effects of Epo (40 000 IU) vs saline on self-reported mood and on neural and cognitive function in healthy volunteers 3 days post-administration to test the reliability of the rapid mood improvement and its neuropsychological basis. Neuronal responses during the processing of happy and fearful faces were investigated using functional magnetic resonance imaging (fMRI); facial expression recognition performance was assessed after the fMRI scan. Daily ratings of mood were obtained for 3 days after Epo/saline administration. During faces processing Epo enhanced activation in the left amygdala and right precuneus to happy and fearful expressions. This was paired with improved recognition of all facial expressions, in particular of low intensity happiness and fear. This is similar to behavioral effects observed with acute administration of serotonergic antidepressants. Consistent with our previous finding, Epo improved self-reported mood for all 3 days post-administration. Together, these results suggest that characterization of the effects of Epo in a clinically depressed group is warranted.

AB - Erythropoietin (Epo) has neuroprotective and neurotrophic effects and is a promising candidate for treatment of neurodegenerative and psychiatric disorder. Recently, we demonstrated that Epo modulates memory-relevant hippocampal response and fear processing in human models of antidepressant drug action 1 week post-administration, and improves self-reported mood for 3 days immediately following administration. The present study explored the effects of Epo (40 000 IU) vs saline on self-reported mood and on neural and cognitive function in healthy volunteers 3 days post-administration to test the reliability of the rapid mood improvement and its neuropsychological basis. Neuronal responses during the processing of happy and fearful faces were investigated using functional magnetic resonance imaging (fMRI); facial expression recognition performance was assessed after the fMRI scan. Daily ratings of mood were obtained for 3 days after Epo/saline administration. During faces processing Epo enhanced activation in the left amygdala and right precuneus to happy and fearful expressions. This was paired with improved recognition of all facial expressions, in particular of low intensity happiness and fear. This is similar to behavioral effects observed with acute administration of serotonergic antidepressants. Consistent with our previous finding, Epo improved self-reported mood for all 3 days post-administration. Together, these results suggest that characterization of the effects of Epo in a clinically depressed group is warranted.

KW - Adult

KW - Affect

KW - Cognition

KW - Double-Blind Method

KW - Emotions

KW - Erythrocyte Count

KW - Erythropoietin

KW - Facial Expression

KW - Female

KW - Hematocrit

KW - Hemoglobins

KW - Humans

KW - Image Processing, Computer-Assisted

KW - Magnetic Resonance Imaging

KW - Male

KW - Oxygen

KW - Photic Stimulation

KW - Recognition (Psychology)

KW - Recombinant Proteins

KW - Social Perception

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/sj.npp.1301439

DO - 10.1038/sj.npp.1301439

M3 - Journal article

C2 - 17473836

SN - 0893-133X

VL - 33

SP - 611

EP - 618

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

IS - 3

ER -

Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this